Splenic marginal zone lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (16 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Splenic marginal zone lymphoma}} | {{Splenic marginal zone lymphoma}} | ||
{{CMG}}, {{AE}} {{AS}} | {{CMG}}, {{AE}}{{Affan}}, {{AS}} | ||
__NOTOC__ | |||
==Overview== | ==Overview== | ||
There is no standardized treatment of [[splenic marginal zone lymphoma]] ([[SMZL]]) The optimal therapy depends on the clinical presentation. [[Asymptomatic]] patients may only be observed routinely without any treatment as it is an indolent tumor. [[Symptomatic]] patients may treated with either [[surgery]], [[immunotherapy]], [[chemotherapy]], immunochemotherapy or [[antiviral]] drugs. Both [[surgery]] and [[immunotherapy]] are equally effective but recently [[immunotherapy]] is considered as a better treatment option as there is no risk of complications that are associated with [[surgery]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
The | The optimal therapy for '''[[splenic marginal zone lymphoma]]''' ('''[[SMZL]]''') depends on the clinical presentation. Treatment options for the condition are as under: | ||
{| | ===Watchful waiting=== | ||
* It is a slow growing tumor so patients may not need treatment right away unless [[symptomatic]]. [[Asymptomatic]] patients may be observed every 3-6 months.<ref name="pmid18094718">{{cite journal |vauthors=Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA |title=Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria |journal=Leukemia |volume=22 |issue=3 |pages=487–95 |date=March 2008 |pmid=18094718 |doi=10.1038/sj.leu.2405068 |url=}}</ref> | |||
===Immunotherapy=== | |||
* In the pre-rituximab era '''[[splenectomy]]''' was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but '''[[rituximab]]''' is reported to be more beneficial in old age patients with [[co-morbid]] conditions.<ref name="pmid16700034">{{cite journal |vauthors=Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ |title=Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone |journal=Cancer |volume=107 |issue=1 |pages=125–35 |date=July 2006 |pmid=16700034 |doi=10.1002/cncr.21931 |url=}}</ref> | |||
* '''[[Rituximab]]''' was found to be equally effective when compared to [[splenectomy]] for the treatment of [[splenic marginal zone lymphoma]] ([[SMZL]]) in terms of complete [[remission]] and overall [[survival]] of the patient with no [[complications]] of the [[surgical procedure]].<ref name="pmid20350661">{{cite journal |vauthors=Bennett M, Schechter GP |title=Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab |journal=Semin. Hematol. |volume=47 |issue=2 |pages=143–7 |date=April 2010 |pmid=20350661 |doi=10.1053/j.seminhematol.2010.01.004 |url=}}</ref><ref name="pmid23345547">{{cite journal |vauthors=Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP |title=Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy |journal=Oncologist |volume=18 |issue=2 |pages=190–7 |date=2013 |pmid=23345547 |pmc=3579603 |doi=10.1634/theoncologist.2012-0251 |url=}}</ref><ref name="pmid27030961">{{cite journal |vauthors=Perrone S, D'Elia GM, Annechini G, Ferretti A, Tosti ME, Foà R, Pulsoni A |title=Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era |journal=Leuk. Res. |volume=44 |issue= |pages=53–60 |date=May 2016 |pmid=27030961 |doi=10.1016/j.leukres.2016.03.005 |url=}}</ref><ref name="pmid24057925">{{cite journal |vauthors=Olszewski AJ, Ali S |title=Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma |journal=Ann. Hematol. |volume=93 |issue=3 |pages=449–58 |date=March 2014 |pmid=24057925 |doi=10.1007/s00277-013-1900-4 |url=}}</ref><ref name="pmid23016878">{{cite journal |vauthors=Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E |title=Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma |journal=Br. J. Haematol. |volume=159 |issue=3 |pages=322–8 |date=November 2012 |pmid=23016878 |doi=10.1111/bjh.12036 |url=}}</ref> | |||
| | |||
| | ===Chemotherapy=== | ||
| | * [[chemotherapeutic]] drugs such as '''[[cyclophosphamide]]''', '''[[chlorambucil]]''' have been used in the past for the treatment of [[splenic marginal zone lymphoma]] but the results were not favorable.<ref name="pmid8652403">{{cite journal |vauthors=Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G |title=Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hématologie Cellulaire (GFHC) |journal=Br. J. Haematol. |volume=93 |issue=3 |pages=731–6 |date=June 1996 |pmid=8652403 |doi= |url=}}</ref>. | ||
| | * [[Purine]] analogues such as '''[[fludarabine]]''', '''[[pentostatin]]''', have also been used. They are superior to [[alkylating agents]] in terms of [[efficacy]] but not better than [[rituximab]] and in addition to that they have their side effects as well.<ref name="pmid9359516">{{cite journal |vauthors=Bolam S, Orchard J, Oscier D |title=Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes |journal=Br. J. Haematol. |volume=99 |issue=1 |pages=158–61 |date=October 1997 |pmid=9359516 |doi= |url=}}</ref> | ||
| | |||
| | ===Immunochemotherapy=== | ||
| | * Several [[chemotherapy]] [[regimens]] have been used in combination with '''[[rituximab]]'' for the treatment of [[splenic marginal zone lymphoma]] ([[SMZL]]) showing high response rates and prolonged duration of response than [[chemotherapy]] alone.<ref name="pmid23712547">{{cite journal |vauthors=Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M |title=Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up |journal=Ann. Oncol. |volume=24 |issue=9 |pages=2434–8 |date=September 2013 |pmid=23712547 |doi=10.1093/annonc/mdt181 |url=}}</ref><ref name="pmid16700034">{{cite journal |vauthors=Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ |title=Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone |journal=Cancer |volume=107 |issue=1 |pages=125–35 |date=July 2006 |pmid=16700034 |doi=10.1002/cncr.21931 |url=}}</ref> | ||
| | * But addition of [[chemotherapy]] doesn't seem to improve the [[efficacy]] of [[rituximab]].<ref name="pmid23016878">{{cite journal |vauthors=Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E |title=Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma |journal=Br. J. Haematol. |volume=159 |issue=3 |pages=322–8 |date=November 2012 |pmid=23016878 |doi=10.1111/bjh.12036 |url=}}</ref> | ||
|- | ===Antiviral therapy=== | ||
| | * Patients with [[splenic marginal zone lymphoma]] ([[SMZL]]) and [[hepatitis C]] infection who do not require immediate cyto-reductive therapy should be treated with [[antiviral]] therapy as it results in [[tumor regression]] in majority of the cases.<ref name="pmid24799461">{{cite journal |vauthors=Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A |title=Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi |journal=Ann. Oncol. |volume=25 |issue=7 |pages=1404–10 |date=July 2014 |pmid=24799461 |doi=10.1093/annonc/mdu166 |url=}}</ref><ref name="pmid25285757">{{cite journal |vauthors=Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M |title=Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report |journal=J. Hepatol. |volume=62 |issue=1 |pages=234–7 |date=January 2015 |pmid=25285757 |doi=10.1016/j.jhep.2014.09.031 |url=}}</ref> | ||
| | |||
* | |||
|- | |||
| | |||
| | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 34: | Line 31: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Latest revision as of 21:55, 30 January 2019
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma medical therapy |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Splenic marginal zone lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Muhammad Affan M.D.[2], Sowminya Arikapudi, M.B,B.S. [3]
Overview
There is no standardized treatment of splenic marginal zone lymphoma (SMZL) The optimal therapy depends on the clinical presentation. Asymptomatic patients may only be observed routinely without any treatment as it is an indolent tumor. Symptomatic patients may treated with either surgery, immunotherapy, chemotherapy, immunochemotherapy or antiviral drugs. Both surgery and immunotherapy are equally effective but recently immunotherapy is considered as a better treatment option as there is no risk of complications that are associated with surgery.
Medical Therapy
The optimal therapy for splenic marginal zone lymphoma (SMZL) depends on the clinical presentation. Treatment options for the condition are as under:
Watchful waiting
- It is a slow growing tumor so patients may not need treatment right away unless symptomatic. Asymptomatic patients may be observed every 3-6 months.[1]
Immunotherapy
- In the pre-rituximab era splenectomy was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but rituximab is reported to be more beneficial in old age patients with co-morbid conditions.[2]
- Rituximab was found to be equally effective when compared to splenectomy for the treatment of splenic marginal zone lymphoma (SMZL) in terms of complete remission and overall survival of the patient with no complications of the surgical procedure.[3][4][5][6][7]
Chemotherapy
- chemotherapeutic drugs such as cyclophosphamide, chlorambucil have been used in the past for the treatment of splenic marginal zone lymphoma but the results were not favorable.[8].
- Purine analogues such as fludarabine, pentostatin, have also been used. They are superior to alkylating agents in terms of efficacy but not better than rituximab and in addition to that they have their side effects as well.[9]
Immunochemotherapy
- Several chemotherapy regimens have been used in combination with 'rituximab for the treatment of splenic marginal zone lymphoma (SMZL) showing high response rates and prolonged duration of response than chemotherapy alone.[10][2]
- But addition of chemotherapy doesn't seem to improve the efficacy of rituximab.[7]
Antiviral therapy
- Patients with splenic marginal zone lymphoma (SMZL) and hepatitis C infection who do not require immediate cyto-reductive therapy should be treated with antiviral therapy as it results in tumor regression in majority of the cases.[11][12]
References
- ↑ Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.
- ↑ 2.0 2.1 Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ (July 2006). "Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone". Cancer. 107 (1): 125–35. doi:10.1002/cncr.21931. PMID 16700034.
- ↑ Bennett M, Schechter GP (April 2010). "Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab". Semin. Hematol. 47 (2): 143–7. doi:10.1053/j.seminhematol.2010.01.004. PMID 20350661.
- ↑ Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP (2013). "Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy". Oncologist. 18 (2): 190–7. doi:10.1634/theoncologist.2012-0251. PMC 3579603. PMID 23345547.
- ↑ Perrone S, D'Elia GM, Annechini G, Ferretti A, Tosti ME, Foà R, Pulsoni A (May 2016). "Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era". Leuk. Res. 44: 53–60. doi:10.1016/j.leukres.2016.03.005. PMID 27030961.
- ↑ Olszewski AJ, Ali S (March 2014). "Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma". Ann. Hematol. 93 (3): 449–58. doi:10.1007/s00277-013-1900-4. PMID 24057925.
- ↑ 7.0 7.1 Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E (November 2012). "Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma". Br. J. Haematol. 159 (3): 322–8. doi:10.1111/bjh.12036. PMID 23016878.
- ↑ Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G (June 1996). "Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hématologie Cellulaire (GFHC)". Br. J. Haematol. 93 (3): 731–6. PMID 8652403.
- ↑ Bolam S, Orchard J, Oscier D (October 1997). "Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes". Br. J. Haematol. 99 (1): 158–61. PMID 9359516.
- ↑ Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M (September 2013). "Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up". Ann. Oncol. 24 (9): 2434–8. doi:10.1093/annonc/mdt181. PMID 23712547.
- ↑ Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A (July 2014). "Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi". Ann. Oncol. 25 (7): 1404–10. doi:10.1093/annonc/mdu166. PMID 24799461.
- ↑ Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M (January 2015). "Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report". J. Hepatol. 62 (1): 234–7. doi:10.1016/j.jhep.2014.09.031. PMID 25285757.